Biotop-report 2012
Yüklə 0,73 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- ORGANOBALANCE
- EPO Berlin-Buch
- KNAUER
- Scienion
5 BioTOPics 44 | May 2012 Industry BioTOP-Report work in companies with 11-50 employees. More than 52 % of all employees in the region’s biotech industry work for the 19 companies that have more than 50 employees. The thematic fo- cus also remained unchanged in recent years. The main remains biomedicine, and here diagnostics. Deals and product developments The year 2011 saw a range of new cooperation agreements and important milestones in product development. Here are a few selected examples from the wide spectrum of activities:
process engineering and the GMP production of biopharmaceuti- cal active agents, has been very active. The company closed sev- eral license agreements to use their cell lines, including a non- exclusive license agreement with Boehringer Ingelheim to use ProBioGen’s innovative glyco-engineering technology "GlymaxX" Boehringer Ingelheim will use the technology in biopharmaceuti- cal contract development and production. ORGANOBALANCE GmbH signed a worldwide exclusive license agreement with Lonza under which the licensee develops, pro- duces and markets a probiotic lactobacillus strain. The probiotic strain developed by ORGANOBALANCE acts against Helicobacter pylori (H. pylori). The license provides Lonza with the basis for ac- cess to the probiotic market. Group, Germany’s largest private hospital group ++++
The first evaluation data from the clinical study of MGN1601 by MOLOGEN AG in kidney cancer therapy are far more encouraging than expected
The colorectal cancer test Epi proColon ® 2.0 developed by Epigenomics detects 95 % of cancer cases in a clinical trial ++++
Glycotope enrols first patients in phase I trial with TrasGEX (TM), a glycooptimized HER2 biobetter antibody ++++
ATLAS Biolabs joins the bioinformatics project NGSgoesHPC of the German Federal Ministry of Education and Research (BMBF) OCTOBER 2011 Humedics successfully closes its first VC funding contract with Charité Bio- medical Fund, VC-Fonds Technologie, KfW, the German high-tech start-up fund HTGF und Ventegis Capital AG ++++ Epigenomics announces market launch of Epi proColon ® 2.0 CE in Europe ++++ ProBioGen and Inhibrx sign licence deal on GlymaxX ® ADCC technology for therapeutic antibody develop- ment NOVEMBER 2011 MOLOGEN AG achieves the targets of its kidney cancer study with MGN1601 ahead of schedule ++++
co.don AG receives the entrepreneur award of the Eastern German Savings Bank Federation (OSV), one of the most prestigious distinctions awarded in Germany’s eastern federal states
SCIENION founds the US subsidiary SCIENION US, Inc. ++++ The new method developed by the company Caprotec called Capture Compound Mass Spec- trometry is used to research new anti-cancer agents in cooperation with the Leibniz-Institute for Molecular Pharmacology (FMP) ++++
NOXXON com- pletes Phase I trial for the SDF-1 inhibitor NOX-A12 JANUARY 2012 ORGANOBALANCE signs licence agreement with Sanofi Pasteur for access to a modified yeast strain for vaccine applications ++++
EPO starts strategic cooperation with vivoPharm to enhance its market position in the US. FEBRUARY 2012 The Epi proLung ® BL assay by Epigenomics demonstrates good performance as a confirmation test for patients with suspected lung cancer ++++
Con- struction starts on Europe’s largest hospital laboratory in Berlin-Wedding: Groundbreaking ceremony for the operations facility of Labor Berlin – Charité Vivantes GmbH MARCH 2012 ProBioGen's licenses its AGE1.CR ® cell line for viral vaccine production to Ceva ++++
SCIENION introduces sciREADER CL for colorimetric detection of multiplex assays 6 BioTOPics 44 | May 2012 BioTOP-Report Industry EPO Berlin-Buch GmbH has closed a cooperation agreement with vivoPharm, an Australian/American company. vivoPharm also focuses on preclinical pharmacological research and will make the primary tumour models developed by EPO more in- tensively available to cancer research facilities in the USA. For the first time, EPO technologies are therefore giving biotechnol- ogy and pharmaceutics companies in the USA the opportunity to test the cancer medicines they are developing in models that are close to clinical practice and to seek and validate predictive (bio-) markers for their efficacy. In the field of regenerative medicine, co.don AG has signed a framework agreement with Germany’s largest association of clin- ics, the Asklepios Group. It enables Asklepios Clinics throughout Germany to treat patients with the cell-based biological medicine ARTROCELL 3D ® /co.don chondrosphere ® . The product is used for regenerative treatment of cartilage damage, e.g. of the knee, and is an ideal extension of the therapies offered by the Asklepios Hospitals.
with ChromaCon AG, under which ChromaCon grants KNAUER a semi-exclusive license for world-wide marketing, distribution and after-sales services of the Contichrom™ lab-scale preparative chromatography unit for use in discovery, process development and small scale production. In an internationalisation measure, Scienion AG founded an American subsidiary in Princeton to de- velop a base in this important key market and meet the growing Number of Employees According to Company Size In comparison to the previous year, the average number of employees per company increased by 4,5 % in the 1-10 category and decreased by 5 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 10%. (Source: Own survey, BioTOP database, 215 companies questioned, February 2012) 2.200
2.100 2.000
1.900 1.800
1.700 1.600
1.500 1.400
1.300 1.200
1.100 1.000
900 800
700 600
500 400
300 200
100 0
Number of employees 02 03 04 05 06 07 08 09 10 11 2117 19 companies > 51 employees 02 03 04 05 06 07 08 09 10
134 companies 1-10 employees 645 02 03 04 05 06 07 08 09 10 11 62 companies 11-50 employees 1306 Yüklə 0,73 Mb. Dostları ilə paylaş:
|